These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11463129)

  • 1. Visual field defects with vigabatrin: epidemiology and therapeutic implications.
    Kälviäinen R; Nousiainen I
    CNS Drugs; 2001; 15(3):217-30. PubMed ID: 11463129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects.
    Kälviäinen R; Nousiainen I; Mäntyjärvi M; Nikoskelainen E; Partanen J; Partanen K; Riekkinen P
    Neurology; 1999 Sep; 53(5):922-6. PubMed ID: 10496247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding and interpreting vision safety issues with vigabatrin therapy.
    Plant GT; Sergott RC
    Acta Neurol Scand Suppl; 2011; (192):57-71. PubMed ID: 22061181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Visual field disturbances in epileptic patients treated with vigabatrin (sevril)].
    Gross-Tsur V; Lahat E; Banin E; Shahar E; Shalev R
    Harefuah; 2002 Mar; 141(3):247-9, 315. PubMed ID: 11944216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examining visual field defects in the paediatric population exposed to vigabatrin.
    Spencer EL; Harding GF
    Doc Ophthalmol; 2003 Nov; 107(3):281-7. PubMed ID: 14711160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review.
    Maguire MJ; Hemming K; Wild JM; Hutton JL; Marson AG
    Epilepsia; 2010 Dec; 51(12):2423-31. PubMed ID: 21070215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vigabatrin: 2008 update.
    Willmore LJ; Abelson MB; Ben-Menachem E; Pellock JM; Shields WD
    Epilepsia; 2009 Feb; 50(2):163-73. PubMed ID: 19230067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influence of vigabatrin on visual fields and electrophysiological tests in patients with epilepsy].
    Mrugacz M; Bakunowicz-Łazarczyk A
    Klin Oczna; 2003; 105(5):326-8. PubMed ID: 14746191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling the topography of absolute defects in patients exposed to the anti-epileptic drug vigabatrin and in normal subjects using automated static suprathreshold perimetry of the entire 80° visual field.
    Besch D; Schiefer U; Eter N; Burth R; Elger CE; Spitznas M; Dietz K
    Graefes Arch Clin Exp Ophthalmol; 2011 Sep; 249(9):1333-43. PubMed ID: 21380539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Visual field changes secondary to vigabatrin treatment].
    Mauri-Llerda JA; Iñiguez C; Tejero-Juste C; Santos-Lasaosa S; Escalza-Cortina I; Ascaso-Puyuelo J; Abad-Alegría F; Morales-Asín F
    Rev Neurol; 2000 Dec 16-31; 31(12):1104-8. PubMed ID: 11205539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.
    Newman WD; Tocher K; Acheson JF
    Eye (Lond); 2002 Sep; 16(5):567-71. PubMed ID: 12194070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vigabatrin-induced visual dysfunction in Chinese patients with refractory epilepsy.
    Hui AC; Liu DT; Wong KK; Man BL; Leung T; Lam PT; Lam DS
    Eur J Ophthalmol; 2008; 18(4):624-7. PubMed ID: 18609486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual field constriction on vigabatrin.
    Prescrire Int; 2000 Feb; 9(45):210-1. PubMed ID: 11503799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of a unique visual field defect attributed to vigabatrin.
    Wild JM; Martinez C; Reinshagen G; Harding GF
    Epilepsia; 1999 Dec; 40(12):1784-94. PubMed ID: 10612345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vigabatrin-associated visual field defects in children.
    Russell-Eggitt IM; Mackey DA; Taylor DS; Timms C; Walker JW
    Eye (Lond); 2000 Jun; 14 ( Pt 3A)():334-9. PubMed ID: 11026995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vigabatrin-associated bilateral simple optic nerve atrophy with visual field constriction. A case report and a survey of the literature].
    Viestenz A; Viestenz A; Mardin CY
    Ophthalmologe; 2003 May; 100(5):402-5. PubMed ID: 12748807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication.
    Hardus P; Verduin WM; Postma G; Stilma JS; Berendschot TT; van Veelen CW
    Epilepsia; 2000 May; 41(5):581-7. PubMed ID: 10802764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visual field defects in patients taking vigabatrin.
    Midelfart A; Midelfart E; Brodtkorb E
    Acta Ophthalmol Scand; 2000 Oct; 78(5):580-4. PubMed ID: 11037919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study.
    Riikonen R; Rener-Primec Z; Carmant L; Dorofeeva M; Hollody K; Szabo I; Krajnc BS; Wohlrab G; Sorri I
    Dev Med Child Neurol; 2015 Jan; 57(1):60-7. PubMed ID: 25145415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual field defects associated with vigabatrin therapy.
    Lawden MC; Eke T; Degg C; Harding GF; Wild JM
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):716-22. PubMed ID: 10567485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.